The August issue of Dermatology Times featured an article written by dermatologist Darrell Rigel, MD, FAAD, about his 2025 Journal of Drugs in Dermatology study on dermatology clinician perspectives on sunscreen. The study, “Perceptions and Recommendations for Sunscreen: A Cross-Sectional Survey of United States Dermatology Healthcare Providers,” surveyed 723 U.S. clinicians. Nearly all participants (98%) agreed that the “best sunscreen is the one patients will consistently use,” though significantly more dermatologists than physician assistants and nurse practitioners agreed with the statement. Nearly all (99%) of participants agreed that sunscreen helps reduce skin cancer risk. Respondents reported that social media and social media influencers were the greatest source of sunscreen misinformation. The authors note that the survey results strongly support sunscreen use, and more and better patient education is needed on sun protection.
MedPage Today highlighted an August JDD letter to the editor on paradoxical hidradenitis suppurativa (HS) in psoriasis patients on biologics. The letter, “Hidradenitis Suppurativa in Psoriasis Patients Treated With Biologics,” written by researchers at Stony Brook University and Hospital, shared results from a retrospective cohort study utilizing the TriNetX database. Psoriasis patients treated with adalimumab or infliximab were significantly more likely to be diagnosed with HS post-treatment compared to controls, while psoriasis patients on risankizumab or guselkumab were both associated with a significantly decreased risk of developing HS post-treatment. No other biologic therapies included in the study showed significantly different rates of HS compared with controls. The authors encourage greater awareness of the paradoxical onset, and believe understanding the phenomenon may lead to developments in understanding the pathogenesis of HS.
An August JDD study on dietary approaches in psoriasis made news in Healio. The study, “Impact of Intermittent Fasting, Keto Diet vs Continuous Caloric Restriction on Psoriasis Severity: A Systematic Review and Meta-Analysis Protocol,” was conducted by researchers in Saudi Arabia. The systematic review and Meta Analysis found a significant PASI decrease in Keto and continuous caloric restriction cohorts compared with intermittent fasting. The authors note that the benefits of Keto and continuous caloric restriction occurred primarily through substantial weight loss and metabolic improvements. The authors write that the results validate
the use of customized nutritional strategies in psoriasis management.
